The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry

Gerrit Gehring1, Katrin Rohrmann2, Nkacheh Atenchong1

  • 1Institute for Molecular Biology, Hannover Medical School, Hannover, Germany Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

Abstract

Insights

Existing drugs amiodarone, dronedarone, and verapamil effectively inhibit filovirus entry into cells. These ion channel blockers show potential as treatments for severe hemorrhagic fevers caused by filoviruses like Ebola.

Area of Science:

  • Virology
  • Pharmacology
  • Cell Biology

Background:

  • Filoviruses, including Ebola and Marburg viruses, cause severe hemorrhagic fevers with no specific treatments.
  • Filovirus cell entry is a complex process dependent on various cellular factors, presenting a potential target for therapeutic intervention.

Purpose of the Study:

  • To identify existing human-approved drugs with anti-filoviral properties by targeting host cell entry mechanisms.
  • To investigate if drugs approved for other indications could interfere with filovirus cell entry pathways.

Main Methods:

  • Utilized authentic filoviruses and pseudotyped lentiviral particles to screen for compounds inhibiting viral entry.
  • Employed cell-based assays to characterize the mechanism and efficacy of identified inhibitors.

Main Results:

  • Amiodarone, an ion channel inhibitor, demonstrated potent inhibition of filovirus cell entry at therapeutic concentrations.
  • Dronedarone and verapamil also exhibited inhibitory effects on filovirus entry, suggesting a class effect among ion channel blockers.
  • Inhibition was concentration-dependent and primarily host cell-directed, affecting most cell types tested.

Conclusions:

  • Amiodarone, dronedarone, and verapamil are effective inhibitors of filovirus cell entry.
  • These findings suggest repurposed ion channel blockers as potential therapeutic agents against filoviral infections.

Related Concept Videos

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
2.8K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
2.9K
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
4.2K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.9K